JOURNAL OF CLINICAL SURGERY ›› 2022, Vol. 30 ›› Issue (11): 1098-1100.doi: 10.3969/j.issn.1005-6483.2022.11.029

Previous Articles    

Progress of immunotherapy in advanced biliary tract cancer

  

  1. Department of Hepatic Surgery,Eastern Hepatobiliary Surgery Hospital / The Third Affiliated Hospital,Navy Medical University,Shanghai 201805, China
  • Received:2022-10-10 Accepted:2022-10-10 Online:2022-11-20 Published:2022-11-20

Abstract: Biliary tract cancer is one of the digestive system malignances with very poor prognosis.Majority of patients belongs to the advanced stage when diagnosed.Currently,systemic chemotherapy is the standard first-line treatment option for advanced biliary tract cancer.However,the clinical efficacy is not satisfactory.A new era has been coming while the immunotherapy is introduced in the treatment of hepatobiliary cancers.Many clinical studies have been conducted in the treatment of biliary tract cancer with immune checkpoint inhibitor drugs,and the clinical efficacy and safety are acknowledged by the clinicians.Meanwhile,further studies should focus on how to treat biliary tract cancer with immunotherapy drugs more precisely.

Key words: biliary tract cancer, immunotherapy, immune checkpoint inhibitors, chemotherapy, combine therapy

[1] WU Guoqing, ZHOU Sicheng, ZHANG Jing, et al. Safety and efficacy of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal metastases in colorectal cancer after preoperative chemotherapy [J]. JOURNAL OF CLINICAL SURGERY, 2022, 30(9): 823-828.
[2] TIAN Wenze, XIONG Xinkui, XU Dafu, et al. The study of conversion therapy with carrelizumab combined with chemotherapy in unresectable locally advanced esophageal cancer [J]. JOURNAL OF CLINICAL SURGERY, 2022, 30(8): 741-743.
[3] LI Dongliang, LUO Jianfei. Clinical study of laparoscopic surgery and open surgery after neoadjuvant chemotherapy for locally advanced Siewert type Ⅱ/Ⅲ AEG [J]. JOURNAL OF CLINICAL SURGERY, 2022, 30(5): 429-432.
[4] YUAN Tong, HUANG Zhiyong. Hepatocellular carcinoma immunotherapy 4.0 [J]. JOURNAL OF CLINICAL SURGERY, 2022, 30(5): 490-493.
[5] JIN Chenglong, ZHANG Jianguo. Research progress of sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer [J]. JOURNAL OF CLINICAL SURGERY, 2022, 30(4): 386-389.
[6] ZHANG Shun, DING Qiubo, ZHUANG Junlong. 2 cases of immune-related cystitis caused by neoadjuvant immunotherapy for bladder cancer [J]. JOURNAL OF CLINICAL SURGERY, 2022, 30(3): 276-279.
[7] LIU Yongbin, WANG Cheng, LIU Yanjie, et al.. Expression and clinical significance of transcobalamin 1 in colorectal cancer and its lung metastasis tissues [J]. JOURNAL OF CLINICAL SURGERY, 2022, 30(1): 54-57.
[8] LEI Hao, YANG Wenrong, LI Zhonghua.. Effect of OCA2 nucleotide rs4778137 polymorphism on neoadjuvant chemotherapy for triple negative breast cancer [J]. JOURNAL OF CLINICAL SURGERY, 2021, 29(9): 842-846.
[9] . Clinical application of autologous tumor infiltrating lymphocytes combined with antiPD1 antibody in the treatment of advanced hepatocellular carcinoma [J]. JOURNAL OF CLINICAL SURGERY, 2021, 29(8): 743-747.
[10] . Research progress in neoadjuvant treatment of esophageal squamous cell carcinoma [J]. JOURNAL OF CLINICAL SURGERY, 2021, 29(8): 784-787.
[11] LI Jinsui, ZHOU Yao, Pu Lulan, et al.. Clinical study on the prevention of bone marrow suppression induced by AC chemotherapy with mixed nucleoside tablets of breast cancer patients [J]. JOURNAL OF CLINICAL SURGERY, 2021, 29(3): 265-268.
[12] LI Jiang, HUANG Zhiyong.. Advances in immune microenvironment and immunotherapy of hepatocellular carcinoma [J]. JOURNAL OF CLINICAL SURGERY, 2021, 29(11): 1089-1091.
[13] ZHANG Yonghui, ZHANG Chun, FU Fenfen, et al. The value of clinical complete response of primary tumor in predicting pathological complete response of axillary lymph nodes in node-positive breast cancer patients following neoadjuvant chemotherapy [J]. JOURNAL OF CLINICAL SURGERY, 2021, 29(1): 83-86.
[14] LI Bo, CAO Kun, ZUO Shi.. Biological characteristics of biliary tract cancer [J]. JOURNAL OF CLINICAL SURGERY, 2020, 28(8): 790-792.
[15] LI Yiming, QIU Hong.. Advances in chemotherapy and targeted therapy for advanced biliary system malignancies [J]. JOURNAL OF CLINICAL SURGERY, 2020, 28(8): 793-797.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!